A number of research firms have changed their ratings and price targets for Spruce Biosciences (NASDAQ: SPRB):
- 6/9/2026 – Spruce Biosciences is now covered by JonesTrading. They set a “buy” rating and a $135.00 price target on the stock.
- 6/5/2026 – Spruce Biosciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 6/1/2026 – Spruce Biosciences had its price target lowered by HC Wainwright from $200.00 to $150.00. They now have a “buy” rating on the stock.
- 5/27/2026 – Spruce Biosciences had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc..
- 5/14/2026 – Spruce Biosciences had its price target lowered by Citizens Jmp from $170.00 to $150.00. They now have a “market outperform” rating on the stock.
- 4/27/2026 – Spruce Biosciences is now covered by Craig Hallum. They set a “buy” rating and a $140.00 price target on the stock.
Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.
The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.
Featured Stories
- Five stocks we like better than Spruce Biosciences
- Gold Is Testing Its 200-Day SMA—These 3 Mining Stocks Are the Play
- Summer Is Coming–But There’s No End in Sight for This Crypto Winter
- Oil Could Dip, But These 3 Energy Stocks Still Look Built to Win
- What’s Behind the Social Media Controversy Surrounding IonQ?
Receive News & Ratings for Spruce Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spruce Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.
